Nov

    Risk Evaluation and Mitigation Strategies (REMS): Balancing Brand Justification and the Proper Role of Antitrust Enforcers.

    11:30 AM GMT

    Risk Evaluation and Mitigation Strategies (REMS) are designed to ensure the safe distribution of drugs; however, according to the recent GPhA report, REMS may be costing the American health care system $5.4 billion in annual pharmaceutical spending.  Do brand manufacturers have valid justifications for restricting distribution?  How should the courts balance potential efficienices of such behavior against potential anticompetitive effects?  What should be the role of antitrust enforcers in examining and litigating REMS practices? 

    This panel, a follow-on discussion on the previous Health Care and Pharmaceuticals Committee REMS program that debated whether brand pharmaceutical companies have a duty to deal with generics, will explore these and other important questions surrounding the use of REMS.

    Moderator: 

    * Robert Davis, Counsel, Venable LLP

    Speakers:

    * Alex Brill, CEO, Matrix Global Advisors
    * Richard A. Feinstein, Partner, Boies Schiller & Flexner LLP
    * Christine Meyer, Vice President, National Economic Research Associates
    * Jan Rybnicek, Advisor to FTC Commissioner Joshua Wright, Federal Trade Commission

    FREE:  Antitrust Section Members, Government, Nonprofit Employees and Students
    $25.00:  Other Non-members

    Learn about Section membership or call 800-285-2221 to join the source code:  RAT14IP125.  Instructions for accessing the live program will be provided in a confirmation email.  For this and all upcoming events visit:  http://AmBar.org/ATEvents.

    CLE
    The ABA is not seeking CLE credit for this program.

    Audio Archive
    Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.

     

     

     

    $25
    NON-MEMBERS
    $10
    MEMBERS
    $0
    SECTION MEMBERS
    Register Now *Additional discounts may apply at checkout

    Log In to view your rate

    Join now to receive additional discounts
    Join and Buy – NOW
    Risk Evaluation and Mitigation Strategies (REMS): Balancing Brand Justification and the Proper Role of Antitrust Enforcers.

    Event Details

    Format

    Teleconference

    Date

    Nov 19, 2014

    2014-11-19T11:30:00 2014-11-19T12:30:00 Risk Evaluation and Mitigation Strategies (REMS): Balancing Brand Justification and the Proper Role of Antitrust Enforcers.

    Risk Evaluation and Mitigation Strategies (REMS) are designed to ensure the safe distribution of drugs; however, according to the recent GPhA report, REMS may be costing the American health care system $5.4 billion in annual pharmaceutical spending.  Do brand manufacturers have valid justifications for restricting distribution?  How should the courts balance potential efficienices of such behavior against potential anticompetitive effects?  What should be the role of antitrust enforcers in examining and litigating REMS practices? 

    This panel, a follow-on discussion on the previous Health Care and Pharmaceuticals Committee REMS program that debated whether brand pharmaceutical companies have a duty to deal with generics, will explore these and other important questions surrounding the use of REMS.

    Moderator: 

    * Robert Davis, Counsel, Venable LLP

    Speakers:

    * Alex Brill, CEO, Matrix Global Advisors
    * Richard A. Feinstein, Partner, Boies Schiller & Flexner LLP
    * Christine Meyer, Vice President, National Economic Research Associates
    * Jan Rybnicek, Advisor to FTC Commissioner Joshua Wright, Federal Trade Commission

    FREE:  Antitrust Section Members, Government, Nonprofit Employees and Students
    $25.00:  Other Non-members

    Learn about Section membership or call 800-285-2221 to join the source code:  RAT14IP125.  Instructions for accessing the live program will be provided in a confirmation email.  For this and all upcoming events visit:  http://AmBar.org/ATEvents.

    CLE
    The ABA is not seeking CLE credit for this program.

    Audio Archive
    Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.

     

     

     

    Related Products

    Related On-Demand CLE